Parker Institute’s Quest to Make Immunotherapy Work in Solid Tumors

Description

“The most effective therapies in solid tumors are also the most toxic—and we need to fix that,” says Dr. John Connolly, Chief Scientific Officer of the Parker Institute for Cancer Immunotherapy. In this episode of the Vanguards of Health Care podcast, Connolly tells Bloomberg Intelligence analyst Sam Fazeli why managing toxicity is the key to unlocking CAR-T’s potential in solid tumors. They explore the rise of in vivo cell therapies, evolving views on the tumor microenvironment, and why foundational cancer vaccines may shape the future of all immunotherapy. Plus, Connolly shares the clinical trials he’s watching closely, the ones that could flip the script on cancer care.